![OCM Member](https://d2cax41o7ahm5l.cloudfront.net/cs/ocm/pharma-research-2019--george-schroeder-443996363.jpg)
George Schroeder
Executive Director
American Academy of Urgent Care Medicine
USA
Biography
George Schroeder MD, MS, FACEP, FAAUCM- Founder & President of Global Renaissance Enterprises, Corp. in Canada, & NARMPRO , LLC in USA He has served as Clinical Assistant Professor of Emergency Medicine at the University of Central Florida College of Medicine and Executive Director of Medical Affairs for the American Academy of Urgent Care Medicine. He has 33 years of experience in Emergency / Urgent Care Medicine Appointed to the International Scientific Advisory Board - Magellan BioScience & serves on Board of Directors of American Academy of Urgent Care Medicine. He is a certified SSI Open Water SCUBA Diver
Research Interest
Emergency Medicine and Urgent Care Medicine, Marine toxins and Natural product Bioactive marine molecules with Biopharmaceutical potential
Biography
Hans Leuenberger studied experimental physics (PhD thesis in nuclear physics) at the University of Basel. He worked for 12 years at Sandoz (today Novartis), spent a sabbatical at the University of Michigan writing a habilitation thesis in Pharmaceutics. In 1982 he became full professor of Pharmaceutical Technology at the University of Basel. He served as executive Vice-President of the Swiss Academy of Engineering Sciences (www.satw.ch) and as President of its Scientific Council. He was president of the Swiss Society of Pharm. Sciences. Hans mentored over 120 PhD students working today in the Pharm. Industry and published more than 160 papers. He has numerous awards (see www.ifiip.ch/award gallery) and is Dr. h.c. of Mahidol & of Mendeleyev University. Hans is Honorary Member of the Swiss Academy of Engineering Sciences, Fellow of the American Association of Pharmaceutical Scientists, Honorary President of CISDEM (http://institucional.us.es/cisdem/index.php/forum/8-ii-international-forum-cisdem), and a Member of the Real Academy of Pharmacy of Spain, etc.
Research Interest
Pharmaceutical Technology
![OCM Member](https://d2cax41o7ahm5l.cloudfront.net/cs/ocm/pharma-research-2019--alexander-seifalian-1102081566.png)
Alexander Seifalian
CEO and Professor Nanotechnology & Regenerative Medicine
The London BioScience Innovation Centre, London
United Kingdom
Biography
Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at caused of cardiovascular diseases and a year at Johns Hopkins Medical School looking at treatment of liver. He published more than 647 peer-reviewed research papers, and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic tracheaâ€. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology. He has over 15,000 media report from his achievement, include BBC, ITV, WSJ, CNN, and many more. Currently he is working on development and commercialisation of human organs using graphene based nanocomposite materials and stem cells technology.
Research Interest
Nanotechnology